Clinical trial

A Study Comparing SB5 to Humira® in Subjects With Moderate to Severe Rheumatoid Arthritis Despite Methotrexate Therapy

NCT02167139

StatusCOMPLETED

Study typeINTERVENTIONAL

Start date2014-05-01

PhasePHASE3

Study timeline

Study start (unknown)2014-05-01Date precision: month

Registry last updated2017-08-17

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Rheumatoid Arthritisunresolved

Interventions

Humira (adalimumab)DRUG

SB5 (proposed biosimilar to adalimumab)DRUG

Sponsors & collaborators

Samsung Bioepis Co., Ltd.lead sponsor

Mapped research locations

KatowicePoland1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT02167139 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.